Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of inobrodib (CCS1477) alone and in combination in advanced hematologic malignancies
2024-519498-20-00Phase 2Authorised
- Sponsor
- CellCentric
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of inobrodib in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and 1 more (5 arms), sponsored by CellCentric. Primary endpoints: Safety and tolerability of inobrodib as monotherapy and in combination and Safety summaries. Planned start May 2025; status: authorised.
02
Drugs
inobrodib
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-519498-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519498-20-00.